Prescient Therapeutics cut its net loss by 4.4% to $7 million in FY26 while expanding its PTX-100 Phase 2a trial across three continents and securing key regulatory designations in Europe and the US.
- Net loss narrowed 4.4% to $7 million
- PTX-100 Phase 2a trial expands to 12 active sites internationally
- Raised $9.8 million via Share Purchase Plan and placement
- European Orphan Drug Designation granted for PTX-100
- CSIRO collaboration validates PTX-100 mechanism using AI
Clinical Momentum for PTX-100 Across Multiple Markets
Prescient Therapeutics (ASX:PTX) has steadily advanced its lead oncology candidate PTX-100 through its Phase 2a clinical trial in relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL), expanding from a single patient enrolment at the start of FY26 to 26 by year-end, and 28 shortly after. The trial now operates at 12 active clinical sites spanning the United States, Australia, and Italy, with plans to add four more sites in Europe following regulatory authorisation.
This growth in enrolment and geographic reach underscores the unmet medical need PTX-100 aims to address in a rare and challenging blood cancer. The company’s regulatory position also strengthened materially with the European Medicines Agency granting Orphan Drug Designation in November 2025, complementing existing US FDA Fast Track and Orphan Drug status. These designations provide market exclusivity and regulatory benefits that could accelerate PTX-100’s path to approval in two major markets.
Financial Discipline Amid Ongoing R&D Investment
Despite ongoing investment in clinical development and corporate growth, Prescient trimmed its net loss by 4.4% to $7 million for the year ended 30 June 2026, compared to a $7.32 million loss in FY25. This modest reduction was achieved while expanding the clinical program internationally and increasing employment-related expenses, primarily due to higher share-based payments.
The company bolstered its balance sheet with a $9.8 million capital raise through a Share Purchase Plan and placement completed in August 2025, supplemented by a $4.3 million Research and Development Tax Incentive (RDTI) refund received in January 2026. These inflows underpin a cash runway extending into 2027, providing the financial foundation to sustain clinical activities and regulatory progress.
Scientific Validation Through AI-Driven Modelling Collaboration
A highlight of FY26 was Prescient’s collaboration with CSIRO, which employed artificial intelligence and computational modelling to generate a detailed 3D model of PTX-100 binding to its target enzyme GGTase-1. This work demonstrated tight, selective binding that may help PTX-100 maintain efficacy across different target conformations and potentially address resistance mechanisms; a common challenge in oncology drug development.
Prescient CEO James McDonnell emphasised that these insights not only deepen understanding of PTX-100’s mechanism but also guide clinical trial design and patient selection, enhancing the strategic development of the candidate.
Executive Strengthening and Corporate Governance
Prescient strengthened its leadership team with the appointment of Dr Rosalind Wilson as Chief Medical Officer in July 2026. Dr Wilson brings over 30 years of global oncology drug development experience, further bolstering the company’s clinical development capabilities. This transition follows the semi-retirement of former CMO Dr Marissa Lim.
Board and executive continuity remain intact, with Non-Executive Chair Dr James Campbell and CEO James McDonnell credited for steering the company’s clinical and corporate progress amid the complexities of a global trial expansion.
Risks and Regulatory Considerations Ahead
While Prescient’s progress is encouraging, the company continues to face typical biotech sector risks, including the inherent uncertainty of clinical development, potential funding needs beyond the current runway, and possible impacts from proposed reforms to the Australian R&D Tax Incentive program. These reforms, if legislated, could reduce the cash benefits currently supporting Prescient’s R&D activities.
Regulatory approvals remain critical milestones. The Phase 2a trial’s dose optimisation review, expected before the end of 2026, will be closely watched as a key near-term catalyst. The company has flagged Phase 2b as potentially registrational, subject to FDA agreement, which could expedite market entry if successful.
Cell Therapy Platforms Held in Reserve
Prescient’s cell therapy platforms, OmniCAR and CellPryme, have seen limited investment during FY26 as the company prioritises PTX-100’s clinical development. However, business development discussions continue, preserving strategic optionality for these longer-term assets.
As the PTX-100 program advances, the fate and funding of these platforms will be an important aspect to monitor, especially given the evolving landscape of CAR-T and cell therapy technologies.
Bottom Line?
Prescient’s FY26 results reflect disciplined execution and clinical progress, but upcoming Phase 2a data and regulatory milestones will be pivotal in shaping its path forward.
Questions in the middle?
- Will Phase 2a dose optimisation data confirm PTX-100’s clinical promise and inform Phase 2b design?
- How might proposed changes to Australia’s R&D Tax Incentive affect Prescient’s funding strategy?
- What are the prospects for partnering or advancing the OmniCAR and CellPryme platforms amid PTX-100’s prioritisation?